



Journal Homepage: - [www.journalijar.com](http://www.journalijar.com)

## INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/14998  
DOI URL: <http://dx.doi.org/10.21474/IJAR01/14998>



### RESEARCH ARTICLE

#### MEDICATION-FREE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: EMPIRICAL AND MODELING-BASED CASE STUDY

**Mahmoud Huleihil**

The Arab Academic Institute of Education, Beit-Berl College, Kfar Saba 44905, Israel.

#### Manuscript Info

##### Manuscript History

Received: 05 May 2022  
Final Accepted: 08 June 2022  
Published: July 2022

##### Key words:-

Diabetes, Type 2, Low Carbohydrate,  
Sports, Minimal Model

#### Abstract

This study addresses the possibility of medication-free management of type 2 diabetes mellitus (DM). Typical glucose values, in terms of hemoglobin A1C (HbA1C) test results of less than 6.0%, could be attained by consuming low carbohydrate meals and participating in physical exercises without pharmaceutical adjuncts. Four to six meals should be consumed in 12 hours, preferably during the day's activities between six in the morning and six in the evening. It is important to walk for about one hour after the main meal, although a better practice is to wait two to three hours after the main meal before doing so. Such an approach assures low glucose levels at night. When possible, lifting weights to develop muscles can help regulate sugar levels in the blood and maintain homeostasis. There are empirical findings that HbA1C values could be reduced by 0.5 in 23 days. These findings were supported by simulation results based on Bergman's minimal model of blood glucose control. The minimal model is modified to address the role of low-carb meals and physical exercises by simulation and is used to study the effects of different model parameters that represent the liver and muscles. Simulation-based sensitivity analysis is presented, showing positive results toward mitigating type 2 DM.

Copy Right, IJAR, 2022., All rights reserved.

#### Introduction:-

Diabetes mellitus (DM), often simply called diabetes [1-34], is a chronic metabolic disorder in the human body. It is diagnosed as a state of low insulin sensitivity or an insulin-resistant state. The main characteristic of DM is hyperglycemia due to dysfunction of insulin secretion, insulin influence, or both [1]. Usually, DM is classified into type 1 and type 2 [2-4]. Type 1 DM, also known as childhood diabetes, generally arises from the destruction of pancreatic beta cells, leading to a state of insulin deficiency or absence [5]. Type 2 DM, which has usually been associated with adults, has recently gained another name—adolescent diabetes—because of its presence in an increasing number of patients in their late adolescence. It is diagnosed as a state of low insulin sensitivity or an insulin-resistant state. The causes of type 1 DM include autoimmune processes or are due to unknown causes of destruction of pancreatic beta cells. The causes of type 2 DM include factors significantly more focused on lifestyle and genetics [4,6-7]. However, despite the wealth of experience and knowledge concerning the epidemiology, pathophysiology, and medical management of type 2 diabetes in adults, we know little about the disease in children [34].

**Corresponding Author:- Mahmoud Huleihil**

Address:- The Arab Academic Institute of Education, Beit-Berl College, Kfar Saba 44905, Israel.

According to their study [8], DM, especially type 2, is increasing steadily worldwide. The number of affected people is expected to double in the next decade due to increases in the aging population [4]. In 2017, the number of people with DM worldwide was estimated to be 451 million. The expectation is that DM will increase to 552 million by 2030 [4] and to 993 million by 2045 [8].

Conditions of hyperglycemia are associated with symptoms such as frequent urination, thirst, blurred vision, and fatigue [9]. The incentive of lowering glucose levels is linked to reducing or removing health risks and increasing the quality of life of the person with DM [9], without medical treatment for or management of DM, the person with DM will be subject to severe health risks. Some examples of such risks include long-term damage, dysfunction, and failure of different organs, especially those within the vision, urinary, nervous, and circulatory systems. The complications of DM might eventually lead to loss of extremities and, finally, to death. Diabetes mellitus is one of the reasons for the high morbidity rate and mortality [4]. In 2017, 5 million deaths worldwide were attributable to DM in people aged 20 and above [8].

People with DM should consult with their physicians for help and guidance in reducing the levels of blood glucose concentration as they seek a better health status and an improved quality of life. Usually, treatment of type 2 DM includes medication and changes of habit and lifestyle. As was reported by [10], there are different medication treatments, either oral or injectable. It is important to highlight and stress that the responsibility and decision-making for the type of the medication are those of the physician, in consultation with the patient or the patient's guardian or parent. As was pointed out by their research [10], not only are medication treatments essential, but lifestyle changes, as well, are beneficial in type 2 DM management.

Changing eating and sports habits are two important examples of lifestyle changes. Studies by [11-13] found that a low carbohydrate diet reduced glucose concentration. Thus, people with DM might substantially improve their quality of life and reduce health risk factors by seeking a similarly healthy diet. In addition to seeking to maintain a healthy diet, [14-18] found physical activity to be an important factor for managing type 2 DM. Activities such as aerobic exercises, resistance exercises, or both improve glycemic control and reduce health risks.

As pointed out in [18], the type 2 DM condition is highly linked to weight and the inability to control blood sugar levels. This condition forces people with type 2 DM to inject themselves with insulin doses when needed. The insulin hormone regulates and facilitates the movement of sugar into the liver, muscle, and fat cells. As suggested by their study [18], careful scheduling of meals mitigates the need to use insulin and other DM medications. Scheduling could be accomplished by consuming a starch-rich breakfast early in the morning, coupled with a small dinner in the evening.

Diagnostic tools are essential for DM treatment and management. In the following paragraphs, a concise review is given regarding the glucose tolerance test and mathematical modeling.

Mathematical modeling [19 – 33] of glucose homeostasis, insulin-controlled, glucagon-controlled, and insulin-glucagon-controlled systems for people with DM to understand their conditions and associated complications is rapidly growing. When mathematical models are used as diagnostic and treatment tools the understandings, they provide grant new insights into the underlying mechanisms involved.

In [10], the intravenous glucose tolerance test (IVGTT) is a standard diagnostic tool used to assess pre-diabetic and diabetic conditions by measuring blood glucose and insulin changes after exposure to a large bolus of glucose.

Mathematical models [22, 26, 28] widely accompany the analysis of IVGTT results and are used to improve the understanding of blood glucose regulation, offering insights into the relationships between key components such as the dynamics of the relationship between glucose-insulin dynamics and speculation about the effects of different parameters and activities on DM conditions. Similar studies, such as [29], have considered the glucose-insulin-glucagon dynamics.

In the review by [27], based on wisdom gained in the five past decades of modeling in the field, the aims of developing DM models are to understand the dynamics of the glucose levels in the blood and identify potential therapeutic targets for its control and treatment.

Another study highlights the motivation of using mathematical modeling. As was given by [30], mathematical modeling of glucose metabolism has a longstanding tradition. Models have been used for indirectly calculating parameters of physiological interest from experimental data, providing unambiguous quantitative representations of pathophysiological mechanisms, to determining indices of clinical usefulness from simple and practical tests.

In their study [31], the power and strength of mathematical models are demonstrated by analyzing the static and dynamical properties of the proposed models. These models are capable of representing different types of diabetes and other dysfunction in the insulin-glucose system.

Mathematical models can seek good practices. As was shown in [32], the power of a mathematical model was demonstrated by getting good dietary advice such as a daily value of exogenous glucose intake to keep blood glucose within a reasonable range for everyone.

As stated by [33], mathematical modeling can significantly impact our understanding of metabolic regulation. Bergman's minimal model [21, 24, 33] is a part of an extensive number of mathematical models that have enabled the scientific community to understand metabolic physiology, predict the temporal course of metabolic disease development, and design devices to regulate blood sugar more effectively.

In summary, it is possible to conclude that the body of research had gained substantial knowledge regarding type 2 DM and the steadily increasing number of people with DM.

This manuscript highlights and readdresses the risks of type 2 DM and suggests a management method without consuming any medications.

The following hypothesis is raised to seek good results and sustainable diabetes-free conditions: every person with DM can naturally control their blood glucose levels. The means for achieving this goal are threefold: (1) every person with DM should follow a personal schedule of free or low-carb meals; (2) every person with DM should follow a sports plan (walking and muscle building); (3) every person with DM should find the best synchronization between meals and sports.

The wisdom gained is supported empirically by addressing medication-free glucose management for more than 11 years. The study's subject is a person with DM who used lifestyle changes, including general time scheduling and specific types and timing of meals and avoiding all glucose-management pharmaceuticals during the entire study period. The empirical findings were supported by performing sensitivity studies using Bergmann's minimal model for glucose control.

The suggested plan of action includes three steps: (1) a suggestion of a working procedure for type 2 DM management; (2) an explanation of how the procedure works and; (3) a means of motivating self-discipline and adopting responsibility for acting in a way that enables the person with DM to regulate glucose levels without medication. Consultation with the physician is always essential and mandatory.

The manuscript is arranged as follows: materials and methods are addressed in section 2, the self-managing procedure of type 2 DM is given in section 3, simulations by the minimal model of glucose dynamics are given in section 4, numerical examples are given in section 5 and finally, summary and conclusions are given in section 6.

### **Materials and Methods:-**

This study aims to address the need to increase awareness among people with type 2 DM and motivate them to use self-regulation and self-management of their hyperglycemia without pharmaceutical medications, to reduce their blood glucose levels. As mentioned in the introduction, type 2 DM is recognized as a growing global problem. The health risks that the disease poses reduce the quality of life of the person with DM.

### **Hypothesis:**

The central hypothesis of this study is to ensure that, by increasing awareness and changing lifestyle and habits without consuming medications, it is possible to reach normal glucose levels and thus eliminate significant DM-related health risk factors. We hypothesize that it is possible to reduce blood glucose concentration without

medication. If the person with DM follows the suggested procedure, glucose levels below 126 mg/dl, or HbA1C values below 6.0%, could be achieved.

**Research question:**

How can the hypothesized low glucose levels be achieved?

The current research indicates that the targeted objective of self-regulation of glucose levels could be achieved by changing habits, specifically, by adopting personal low-carb meals and by participating in sports.

**Methods:-**

The answer to the research question is achieved by following two paths: The first is the experimental-based case study, where empirical wisdom is gained by evaluating a case study of a person with type 2 DM. The second path follows a simulation-based sensitivity study. With the aid of local health services, data for the project were collected and analyzed over more than 11 years. The study's conclusions, obtained by analyzing collected data, are supported by conducting simulations and performing sensitivity studies based on Bergman's minimal model.

As previously stated, data were collected from the local health services for more than eleven years. The data specifically included two variables—body weight in kilograms (kg) and the percentage of HbA1C in blood. Following the suggested plan of action, conclusions were extracted from the data based on interpreting the changes of the variables concerning time. The data is presented graphically and is arranged in tables.

The sensitivity studies, conducted using Bergmann's minimal model, address the effects of consuming low carbohydrate meals and participating in sports on the dynamics of glucose and insulin and their interaction. The results of the simulations are presented for blood glucose concentration and plasma insulin versus time and their relative integrated effect as a result of  $\pm 20\%$  change in the model parameters. The simulation predictions were interpreted, and conclusions were drawn while relating them to the experimental results.

**Self-managing procedure for type 2 diabetes mellitus - a case study**

This section considers a case study to demonstrate medication-free self-managing glucose levels. It is shown that blood glucose levels below 126 mg/dl are achieved by changing lifestyle habits, including two main activities: 1) consuming low-carb meals; 2) adopting sports activities scheduled between two and three hours after the main meal.

**Observations:-**

At the beginning of 2010, the subject, a 51-year-old, 189 cm high male who weighed 102 kg, discovered by accident that the glucose level in his blood was 500 mg/dl. This shocking high measure of glucose levelled to a panic state characterized by fasting until the following day. After approximately 12 hours, his glucose level had decreased to a value of 250 mg/dl. The new measure gave a hint of what should be done. A decision was made that included two modes of action: changing his eating habits and adopting sports activities.

The clinical tests performed by the local health services showed a glucose level value of 9.0%, measured in terms of HbA1C (see Table 1). This state was characterized and classified by the physician as type 2 DM. The doctor suggested a treatment regimen that included one tablet of metformin per day, to be taken immediately after the subject ate a meal. The subject, however, refused any treatment based on medication and wished to adopt a medicine-free treatment.

The subject's usual daily behavior before making changes included two meals every day. In the early morning, he had breakfast that included a cup of instant coffee with milk (250 cc). At around 19:00, he had dinner that included a plate full of meat (300g), rice (150 g), bread (4 slices), and a cup of soup. Besides those two meals, the subject could eat fruits, cakes, or other sweets, without obstacles or constraints. In short, the subject had poor or no control of his eating habits. Further, because of his work obligations, sports activities were not an option.

The treatment procedure included three phases that were adopted and modified by trial and error, based on experience gained.

**First treatment phase:**

after consulting with a dietitian, the subject changed his eating habits and sports activities as follows:

**Schedule for atypical day:**

A) meals - The day's first meal began at 08:00. The meal included three slices of rice chips with three spoons of cheese cream and one tomato. At 11:00, a second meal provided two eggs, a salad or a tomato, and a banana. At 14:00, the main course was scheduled and included either a meatsteak, a breast of chicken, or fish (300 g), with low-carb vegetables like zucchini, pumpkin, or squash (300 g), and an apple or an orange. The final meal was scheduled at 19:00 and was based on the subject's perception of hunger, with no other constraints placed on consumption; B) sports activity consisting of one hour of walking every morning.

A blood test collected one year later showed that the subject's HbA1C % level had decreased to 6.4 (see Table 1). The treatment included no medications at all. The time variations of HbA1C for the period 2010-2021 are shown in Table 1. Unfortunately, the values of glucose began to increase during the 2016 to 2018 period. Possible explanations of the increase may have been related to a shift of elements of the treatment procedure, breaking the specified habits of low-carb meals, or a decreased sense of obligation to continue sports activities. The increased values in the HbA1C % level alerted that something was not proper in the schedule.

One day, after eating dinner, a dish full of green wheat caused the subject fell asleep for two hours while experiencing profuse perspiration. A home gluco set determined that the subject's glucose level was 190 mg/dl two hours after the meal. Again, this was alarming and made mandatory the second change in behavior.

**Second treatment phase:**

This phase was like the first, with two modifications. The first change was to remove the 19:00 meal (dinner) or replace it with a tomato salad with 300g of yogurt. The second change replaced the previously scheduled one hour morning with one hour evening walk which started two to three-hours after the 14:00 meal. Good results were achieved in 2019 (see Tables 1 and 2).

In early 2020, however, SARS-CoV-2 (the official name of the virus that causes COVID-19) changed the face of the world. In March 2020, the Israeli government closed the country. This closure, or lockdown, dictated the need for a new procedure to treat DM.

**Third treatment phase:**

This phase was like phase two, except walking was not allowed. Instead of walking, a 2kg set of weights (see Figure 1) strengthened and built arm muscles. After half a year, the weight of the set was increased to 4 kg.



**Figure 1:-** 2 kg practicing set, extracted from <https://www.amazon.co.uk/Generic-Dumbbell-Weights-Dumbbell-Dumbbells/dp/B07MFZNSGR>.

As mentioned earlier, local health service personnel performed periodic blood tests on the subject. Values of the HbA1c are given in Table 1.

**Table 1:-** Values of HbA1C versus date between the years 2010 and 2021.

| Date       | HbA1C % |
|------------|---------|
| 04/03/2010 | 9.0     |
| 10/03/2011 | 6.4     |
| 27/10/2011 | 6.6     |
| 09/06/2013 | 6.6     |
| 30/11/2014 | 6.4     |
| 30/04/2015 | 6.2     |
| 09/05/2016 | 7.0     |
| 01/06/2017 | 7.0     |
| 30/08/2018 | 7.9     |
| 18/06/2019 | 7.1     |
| 11/07/2019 | 6.6     |
| 02/10/2019 | 5.8     |
| 09/01/2020 | 6.1     |
| 25/06/2020 | 6.0     |
| 22/10/2020 | 6.0     |
| 03/08/2021 | 6.5     |

Similarly, subject's body weight values are given in Table 2.

**Table 2:-** Values of body weight versus date between the years 2010 and 2021.

| Date       | Weight (kg) |
|------------|-------------|
| 04/03/2010 | 101.8       |
| 04/03/2012 | 97          |
| 01/06/2013 | 94          |
| 30/11/2014 | 102         |
| 30/12/2014 | 100         |
| 09/05/2016 | 103         |
| 01/06/2017 | 101         |
| 01/10/2019 | 98          |
| 22/10/2020 | 92          |
| 23/08/2021 | 98          |

Body weight values are plotted against dates and given in Figure 2.




Figure 2:- Body weight versus date for the period 2010 – 2021. See Table 2 for tabulated values.

Figure 2 demonstrates the changes in the subject's body weight that were attained following the suggested plan. Body weight values were reduced from 102 kg in 2010 to 94 kg in 2013. Then body weight increased and reached values of 102 kg in 2014 and 103 kg in 2016. By 2020 body weight decreased again, to 92 kg. These values corresponded to the three phases of treatment.

Similarly, Figure 3 demonstrates the changes in HbA1C.




Figure 3:- Values of HbA1C% versus date for the period 2010 – 2021. See Table 1 for tabulated values.

Figure 3 demonstrates the changes in HbA1C attained following the suggested plan. The HbA1C values decreased from 9.0 % to 6.4% at the end of the first year of lifestyle habit changes. These values stayed at values slightly above 6% until 2015. These value changes are most likely related to the subject's loss of discipline and patience and are less likely to a decrease of the subject's obligation to the action plan. However, although by 2018, the values of HbA1C had increased and reached 7.9%. This increased value motivated the subject to return to stricter adherence to the action plan.

Here comes the great discovery of what should be done (see phase two of treatment). The importance of walking after the main meal was under focus. Blood tests were collected three weeks after phase two was implemented. Those test results were used to determine the effect of delaying the walking time until two to three hours after the main meal. On June 18, 2019, HbA1C% was 7.1, resulting in phase 2 schedule changes. Approximately three weeks later, on July 11, 2019, the HbA1C% value decreased to 6.6, a 0.5 reduction (difference between the consecutive values) in 23 days. Eventually, the HbA1C% value reached 5.8 by October 2, 2019.


The encouraging test results for HbA1C changes continued to deliver results at a 6.0% level, even when virus-imposed restrictions had a chilling effect on worldwide behavior. Phase three treatment, which included muscle-building of the subject's arms, showed that it is possible to practice sports at home even when restrictions deterred prolonged walking.

Weight and HbA1C values were extracted from Tables 1 and 2, then arranged in Table 3 for the convenience of the reader.

**Table 3:-** Values of body weight and HbA1C during the 2010-2021 period.

| Year | Weight | HbA1C |
|------|--------|-------|
| 2010 | 101.8  | 9     |
| 2013 | 94     | 6.6   |
| 2014 | 102    | 6.4   |
| 2016 | 103    | 7     |
| 2017 | 101    | 7     |
| 2019 | 98     | 5.8   |
| 2020 | 92     | 6     |
| 2021 | 98.5   | 6.5   |


These values are plotted and presented in Figure 4.



**Figure 4:-** HbA1C (%) - left axis) and body weight (kg – right axis) versus date. (See Table 3 for tabulated values).



Figure 4 shows values of HbA1C and body weight versus date. A correlation between the two variables is demonstrated in the figure (e.g., both either decrease or increase). This correlation could be explicitly shown as it is in Figure 5.



**Figure 5:-** Values for HbA1C versus body weight in the year range 2010 – 2021. (See Table 3 for tabulated data).

Figure 5 demonstrates the correlation between HbA1C and body weight. Although the  $R^2$  value is low, the direction of the correlated line (dotted line) is clear.

In summary, the suggested procedure for changing lifestyle or habits, of eating and doing sports, either by walking or by practicing muscle building, can control body weight and HbA1C, and a state of desired values is reached. It is essential to note that the patience and self-discipline of a person with DM could control the specified state variables (body weight and HbA1C) by adopting this procedure. While doing that, consultation with the physician and local health services representatives is mandatory.


### Simulations by a minimal model of glucodynamics

#### Glucose homeostasis and its importance

The human body requires a stable and continuous flow of glucose to maintain its normal behavior. Steady glucose supply comes from the intrinsic hormonal-based control system and the consuming and producing organs of the human body.

Glucose is essential for living cells, and its level should be in a narrow range of 70 – 100 mg/100ml for a risk-free experience [1]. After a rich dose of carbohydrates, the glucose is absorbed from the intestine into the circulating blood in normal subjects. The elevated glucose levels trigger the control system, and the insulin hormone is secreted from the pancreas. This action, in turn, reduces the glucose level as a means of maintaining homeostasis. The glucose is used for fatty acid synthesis, storage as glycogen, protein synthesis, and adenosine triphosphate (ATP) formation.

Insulin lowers blood glucose by increasing glucose uptake in muscle and adipose tissue and promoting glycolysis and glycogenesis in the liver and muscle. Figure 6<sup>1</sup> summarizes a few of the insulin functions towards reducing the high glucose level in the blood.



**Figure 6:-** Schematics of a glucose control system in the human body.

With lower glucose levels, the pancreas releases the glucagon hormone, which has the opposite effect of insulin. As a result of its action, glucose is released from the liver by breaking down glycogen.

In type 2 DM, glucose homeostasis is more complicated, and medical intervention is required. Mathematical models enhance understanding of the effects of several parameters by simulation and design better experiments and controllers (artificial pancreas).

This section reviews Bergman's minimal model [21, 23, 24, 33], using the same notations. The dynamics of the state variables are evaluated concerning their baseline values. Our study uses the minimal model to perform sensitivity analyses, which simulate different processes and actions that a person with DM subject could perform.

### **Bergman's minimal model**

In their study [21], the researchers introduced and applied the minimal model approach as a tool for evaluating glucose tolerance in humans. The purpose of their study was to determine the specific contributions of pancreatic responsiveness and insulin sensitivity to normal and low glucose tolerance in lean and obese subjects.

In this article, the minimal model is used as a tool for sensitivity studies and evaluation of the model's response to  $\pm 20\%$  changes in the model's parameters.

Bergman's minimal model of glucose control includes the three interacting compartments of glucose, remote insulin, and plasma insulin. At the detection of increased glucose levels, the beta cells of the pancreas release insulin into the blood, which enters the interstitial fluid (the remote insulin compartment). This entry of insulin into the interstitial fluid causes a delayed effect on plasma insulin.

<sup>1</sup>Figure 6 is based on "Essentials of Anatomy & Physiology", 4th Edition Martini /Bartholome, Copyright © 2007 Pearson Education, Inc., publishing as Benjamin Cummings. PowerPoint® Lecture Outlines prepared by Alan Magid, Duke University.

As described by their study [21], the minimal model accounts for glucose return to the basal value after injection. A critical experimental discovery was that the effect of insulin needed to be delayed; in fact, insulin slowly leaks into the blood plasma to enter the interstitial fluid before acting on skeletal muscle.




Figure 7:- Schematics of Bergman's minimal model.

Each compartment (see Figure 7) accounts for one variable degraded exponentially, based on its value. The remaining equations account for the rate of substance accumulations in the compartment, which is affected by the input and output rates. The equations of the different compartments are given in the following subsections.

**Glucose compartment**

While above baseline level, plasma glucose is reduced by its uptake in the liver and peripheral tissues, which are activated by the uptake ability X due to the action of insulin in the remote compartment. The time rate change of glucose is given by:

$$\frac{dG}{dt} = -p_1(G - G_b) - p_l X G, \tag{1}$$

where G is the plasma glucose concentration in mg/100ml (or mg/dl), p<sub>1</sub> is the non-insulin-dependent rate constant of tissue glucose uptake in 1/min, G<sub>b</sub> is the basal glucose concentration in mg/dl, p<sub>l</sub> is the sensitivity factor (introduced in the study – to account for liver function), and X is the insulin-dependent uptake ability (remote insulin) in 1/min. The initial glucose condition is given by:

$$G(t=0) = G_i \tag{2}$$

**Remote insulin compartment**

Uptake ability X increases with the plasma insulin concentration and is degraded proportionally to its value. The time rate change of X is given by:

$$\frac{dX}{dt} = -p_2 X + p_3 (I - I_b), \tag{3}$$

where p<sub>2</sub> is the relaxation constant of the uptake ability by remote insulin, in 1/min, p<sub>3</sub> is the uptake ability constant contributed by plasma insulin, in ml/μU·min<sup>2</sup>, I is plasma insulin, in μU/ml, and I<sub>b</sub> is the insulin baseline concentration, in μU/ml. The initial condition of X is given by:

$$X(t=0) = X_i = 0 \tag{4}$$

**Plasma Insulin compartment**

The plasma insulin concentration is increased by secretion from the pancreas and decreased by decay in the plasma. The time rate change of plasma insulin is given by:

$$\frac{dI}{dt} = -n(I - I_b) + \gamma [G - h] + t, \tag{5}$$

where  $n$  is the decay constant of plasma insulin in 1/min,  $\gamma$  is the rate constant of pancreatic release in 1/min,  $h$  is a glucose threshold for which the insulin increase is proportional to glucose level for the specified time interval when  $G > h$ .

Equation (5) could be written more explicitly as follows:

$$\frac{dI}{dt} = \begin{cases} -n(I - I_b) + \gamma(G - h) & \text{when } G > h \\ -n(I - I_b) & \text{when } G \leq h \end{cases} \quad (6)$$

The initial condition of plasma insulin is given by:

$$I(t=0) = I_i \quad (7)$$

**Minimal model-based sensitivity studies**

As one could quickly note, equations (1) – (7) include several parameters that enable the ability to conduct sensitivity analyses. The numerical solution of these equations is done by using the VBA programming language of the Microsoft Excel application. The first-order differential equations are solved by the Runge-Kutta 4<sup>th</sup> order method (see appendix 1).

The sensitivity study based on the minimal model is performed as follows: The baseline case is arbitrarily taken as the lean subject number 1 [21] for each of the parameters given in the following subsections, which are changed by  $\pm 20\%$ . Using the simulation program (see appendix 1), the integrated insulin and glucose concentrations over 120 min are calculated and compared to those calculated for the baseline case. The integral of the glucose values  $A_G$  over a period  $\tau$  is given by:

$$A_G(\tau, \alpha p) = \int_0^\tau G(t, \alpha p) dt, \quad (8)$$

where  $p$  is the sensitivity parameter, and  $\alpha$  takes the values 1, 0.8, and 1.2 to account for the  $\pm 20\%$  change in each parameter. The relative change of integrated glucose concentration is calculated as follows:

$$RA_G(\alpha) = \left( \frac{A_G(\tau, \alpha p) - A_G(\tau, p)}{A_G(\tau, p)} \right) \cdot 100\% \quad (9)$$

Similarly, the integral of the insulin values  $A_I$  over a period  $\tau$  is given by:

$$A_I(\tau, \alpha p) = \int_0^\tau I(t, \alpha p) dt, \quad (10)$$

where  $p$  is the sensitivity parameter, and  $\alpha$  takes the values 1, 0.8, and 1.2 to account for  $\pm 20\%$  change in each parameter. The relative change of integrated insulin concentration is calculated as follows:

$$RA_I(\alpha) = \left( \frac{A_I(\tau, \alpha p) - A_I(\tau, p)}{A_I(\tau, p)} \right) \cdot 100\% \quad (11)$$

The parameters studied are summarized in Table 4.

**Table 4:-** Attributes of model parameters-name, units, and definition.

| Parameter number# | Name     | Units                          | Definition  |
|-------------------|----------|--------------------------------|---|
| 1                 | $p_1$    | 1/min                          | glucose clearance rate independent of insulin                         |
| 2                 | $p_2$    | 1/min                          | rate of clearance of remote insulin                                   |
| 3                 | $p_3$    | ml/ $\mu$ U · min <sup>2</sup> | increase in uptake ability caused by insulin                          |
| 4                 | $n$      | 1/min                          | rate of blood insulin decay   |
| 5                 | $\gamma$ | $\frac{\mu U}{mg \cdot min^2}$ | rate of pancreatic release after glucose bolus                        |
| 6                 | $l$      | Sensitivity factor             | increase or decrease factor multiplying the term $XG$ in equation (1) |

**Numerical examples**

In this section, we consider numerical experiments. Data were extracted from reference [21]. For the reader's convenience, these data are given in the following tables. (Bergman's minimal model parameters and their initial and base values – see Tables 5 and 6).

**Table 5:-** Model parameters extracted from [21].

| #  | $p_1 \cdot 10^2$ | $p_2 \cdot 10^2$ | $p_3 \cdot 10^6$ | $\gamma \cdot 10^3$ | h    | N    |
|----|------------------|------------------|------------------|---------------------|------|------|
| 1  | 2.96             | 1.86             | 6.51             | 5.36                | 90.9 | 0.23 |
| 6  | 1.36             | 3.41             | 17.30            | 0.89                | 90.9 | 0.22 |
| 9  | 4.00             | 0.42             | 2.56             | 3.72                | 154  | 0.22 |
| 12 | 1.80             | 1.08             | 2.29             | 3.42                | 153  | 0.13 |

**Table 6:-** Initial and base values of glucose(mg/100ml) and insulin ( $\mu$ U/ml),extracted from [21].

| #                          | $G_i$ | $I_i$ | $G_b$ | $I_b$ |
|----------------------------|-------|-------|-------|-------|
| 1<br>lean good tolerance   | 298   | 333   | 94    | 17    |
| 6<br>lean low tolerance    | 296   | 50    | 98    | 4     |
| 9<br>obese good tolerance  | 297   | 209   | 100   | 8     |
| 12<br>obese good tolerance | 256   | 99    | 110   | 26    |

A typical response of the minimal model is given in Figures 8 and 9, which illustrate the behavior of glucose and insulin concentrations versus time, based on the numerical simulation of the model.

The glucose concentrations for the subjects considered in this study are given in Figure 8.





Figure 8:- Glucose concentrations (G1, G6, G9, G12) are plotted versus time for four subjects (1, 6, 9, 12) whose data are given in [21].

The solid lines in Figure 8 show simulation results of Bergman's minimal model for the specified subjects. Similarly, the insulin concentrations for the subjects considered in this study are given in Figure 9.



**Figure 9:-** Insulin concentrations (I1, I6, I9, I12) are plotted versus time for four subjects (1, 6, 9, 12) whose data are given in [21].

The solid lines in Figure 9 show simulation results of Bergman's minimal model for the specified subjects.

In the remainder of this section, we report the results of the sensitivity analyses we performed. The response times (120 minutes range) of the glucose and insulin concentration variables are calculated for three values of each parameter considered in the model ( $1 \pm 20\%$ ), as was described in the previous section. The calculated results are plotted and shown in Figures 10-21.

**Sensitivity of parameter  $p_1$  to  $\pm 20\%$**

The results of  $\pm 20\%$  changes in  $p_1$  values are given in figure 10 (glucose concentration) and figure 11 (insulin concentration).




Figure 10:- Glucose concentrationG1 is plotted versus time for three values of p<sub>1</sub>.

Parameter p<sub>1</sub> is the glucose clearance rate independent of insulin.





Figure 11:- Insulin concentrationI1 is plotted versus time for three values of p<sub>1</sub>.

When  $p_1$  was increased, the glucose concentration decreased relative to its reference value (see Figure 10). This effect leads to a reduction in insulin values (see Figure 11). The opposite occurred when  $p_1$  had been lowered. The same effect could be achieved by consuming low-carbs meals or by participating in sports.

#### Sensitivity of parameter $p_2$ to $\pm 20\%$

The results of  $\pm 20\%$  changes in  $p_2$  values are given in figure 12 (glucose concentration) and figure 13 (insulin concentration).



**Figure 12:-** Glucose concentrationG1 is plotted versus time for three values of  $p_2$ .






Figure 13:- Insulin concentrationI1 is plotted versus time for three values of  $p_2$ .

Parameter  $p_2$  is the rate of clearance of remote insulin. When  $p_2$  was increased, the glucose concentration increased relative to its reference value. This effect leads to a reduction in insulin values. The opposite occurred when  $p_2$  was lowered. (See Figures 12 and 13).

**5.3 Sensitivity of parameter  $p_3$  to  $\pm 20\%$**

Parameter  $p_3$  is the parameter of uptake-ability-caused insulin.




Figure 14:- Glucose concentrationG1 is plotted versus time for three values of  $p_3$ .




Figure 15:- Insulin concentrationI1 is plotted versus time for three values of  $p_3$ .

When  $p_3$  was increased, the glucose concentration decreased relative to its reference value. This effect leads to a reduction in insulin values. The opposite occurred when  $p_3$  was lowered. (See Figures 14 and 15).

**Sensitivity of parameter  $\gamma$  to  $\pm 20\%$**

Parameter  $\gamma$  is the parameter of the rate of pancreatic release after glucose bolus.




Figure 16:- Glucose concentrationG1 is plotted versus time for three values of  $\gamma$ .




Figure 17:- Insulin concentrationI1 is plotted versus time for three values of  $\gamma$ .

When  $\gamma$  was increased, the glucose concentration decreased relative to its reference value. This effect leads to an increase in insulin values. The opposite occurred when  $\gamma$  was lowered. (See Figures 16 and 17).

**Sensitivity of parameter n to  $\pm 20\%$**

Parameter n is the parameter of the decay rate of blood insulin.




Figure 18:- Glucose concentrationG1 is plotted versus time for three values of n.




Figure 19:- Insulin concentration  $I_1$  is plotted versus time for three values of  $n$ .

When  $n$  was increased, the glucose concentration increased relative to its reference value. This effect leads to a decrease in insulin values. The opposite occurred when  $n$  was lowered. (See Figures 18 and 19).

**Sensitivity of parameter  $p_l$  to  $\pm 20\%$**

Parameter  $p_l$  is introduced in this study to model liver activity (release or store).




Figure 20:- Glucose concentration  $G_1$ , is plotted versus time for three values of  $p_l$ .




Figure 21:- Insulin concentrationI1 is plotted versus time for three values of p1.

When p1 was increased, the glucose concentration decreased relative to its reference value. This effect leads to a decrease in insulin values. The opposite occurred when p1 was lowered. (See Figures 20 and 21).

Figures 10-21 illustrated the variations of glucose and insulin concentrations with respect to time, visually.

The integrated relative changes of glucose and insulin (Equations 9 and 11) are summarized in Table 7.

Table 7:- Integrated relative changes of glucose and insulin calculated using Equations 9 and 11.

| Parameter<br>Sensitivity value<br>±20% | Integrated glucose relative change % |      | Integrated insulin relative change % |      |
|--|--------------------------------------|------|--------------------------------------|------|
|  | -20%                                 | +20% | -20%                                 | +20% |
| p1                                     | 3.2                                  | -2.6 | 8                                    | -6.2 |
| p2                                     | -1.3                                 | 1.1  | -0.5                                 | 0.5  |
| p3                                     | 2.9                                  | -2.6 | 3.7                                  | -2.8 |
| γ                                      | 1.3                                  | -1.2 | -6.7                                 | 6.6  |
| n                                      | -3                                   | 2.2  | 13.9                                 | -8.8 |
| p1                                     | 2.9                                  | -2.6 | 3.7                                  | -2.8 |

Table 7 quantitatively demonstrate the sensitivity effects of the various parameters. These effects fall in the range 0 – 10%.

### Section 6: Summary and Conclusions:-

This study sought to suggest a treatment procedure to manage type 2 DM without medications. A case study was considered, and an approach to control blood glucose levels was described. The treatment procedure included three phases that were adopted by a trial and error process that was modified according to life constraints and the quality of achieved results. Data were collected during 11 years of treatment. Results included a reduction in HbA1C values from 9.0% to a minimum of 5.8%. This result was achieved by a low-carb diet and by adopting a sports regimen that encompassed walking or lifting small weights to strengthen arm musculature or both.

A sensitivity study based on Bergman's minimal model was introduced to support the experimental findings. It was shown that by changing the parameters of the minimal model, the model variables responded accordingly. Numerical examples were given in section 5.

It is important to stress that there were no prescription medications in the treatment procedure and that the subject remained medication-free throughout treatment. Eating foods with low carbohydrate content will reduce glucose levels in the blood, especially when coupled with participating in sports. These effects could be found in the minimal model while considering the insulin-independent terms, including  $p_1$ ,  $p_l$ , and  $\gamma$  (see Table 7 for numerical values).

In conclusion, if desired blood glucose levels could be achieved by changing lifestyle and habits and by adopting a proper treatment procedure, then medications are unnecessary. Most importantly, the subject must act under the umbrella of local health services and the family physician.

The findings outlined herein motivate the need to continue this research protocol, consider more cases to classify the personal needs for each case, and study the complexity of the problem. Such an investigation could be continued at centers where the primary focus is directed to treating and counseling people with DM.

### Data Availability

The data used to support the findings of this study are included in the article.

### Conflicts of Interest

The author declares that he has no conflicts of interest.

### References:-

1. American Diabetes Association, "Diagnosis and Classification of Diabetes Mellitus," *Diabetes Care* Volume 37, Supplement 1, pp. 581-590, 2014.
2. Sin Yee Tan, Joyce Ling Mei Wong, Yan Jinn Sim, Su Sie Wong, Safa Abdelgadir Mohamed Elhassan, Sean Hong Tan, Grace Pei Ling Lim, Nicole Wuen Rong Tay, Naveenya Chetty Annan, Subrat Kumar Bhattamisra, Mayuren Candasamy, Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention, *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, Volume 13, Issue 1, pp.364-372, 2019, ISSN 1871-4021, <https://doi.org/10.1016/j.dsx.2018.10.008>. (<http://www.sciencedirect.com/science/article/pii/S1871402118304181>)
3. Kharroubi, A. T., & Darwish, H. M., "Diabetes mellitus: The epidemic of the century", *World journal of diabetes*, 6(6), pp. 850–867, 2015. <https://doi.org/10.4239/wjd.v6.i6.850>
4. Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. , "Type 2 diabetes mellitus: a review of current trends", *Oman medical journal*, 27(4), 269–273, 2012. <https://doi.org/10.5001/omj.2012.68>
5. Zubin Punthakee MD, MSc, FRCPC, Ronald Goldenberg MD, FRCPC, FACE, Pamela Katz MD, FRCPC, "Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome", Volume 42, Supplement 1, pp. S10–S15, 2018. OI: <https://doi.org/10.1016/j.jcjd.2017.10.003>
6. DeFronzo, R., Ferrannini, E., Groop, L. et al., "Type 2 diabetes mellitus", *Nat Rev Dis Primers* 1, 15019, 2015. <https://doi.org/10.1038/nrdp.2015.19>
7. Frank B. Hu, MD, PHD, "Globalization of Diabetes: The role of diet, lifestyle, and genes", *Diabetes Care*, 34(6): 1249 -, 2011.1257. <https://doi.org/10.2337/dc11-0442>

8. N.H. Cho, J.E. Shaw, S. Karuranga, Y. Huang, J.D. da Rocha Fernandes, A.W. Ohlrogge, B. Malanda, "IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045", *diabetes research and clinical practice* 138, pp. 271 – 281, 2018. DOI:<https://doi.org/10.1016/j.diabres.2018.02.023>
9. Melanie J. Davies, David A. D'Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tzapas, Deborah J. Wexler, and John B. Buse, "Management of Hyperglycemia in Type 2 Diabetes", A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) *Diabetes Care*, 41, pp. 2669–2701, 2018. | <https://doi.org/10.2337/dci18-0033>
10. Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Del Cañizo-Gómez, F. J., "Update on the treatment of type 2 diabetes mellitus", *World journal of diabetes*, 7(17), pp. 354–395, 2016. <https://doi.org/10.4239/wjd.v7.i17.354>
11. Yan Meng, Hao Bai, Shijun Wang, Zhaoping Li, Qian Wang, Liyong Chen, "Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: A systematic review and meta-analysis of randomized controlled trials", *Diabetes Research and Clinical Practice*, VOL. 131, pp. 124-131, 2017. 2017 DOI:<https://doi.org/10.1016/j.diabres.2017.07.006>
12. L. M. Castañeda-González, M. Bacardí Gascón and A. Jiménez Cruz, "Effects of low carbohydrate diets on weight and glycemic control among type 2 diabetes individuals: a systemic review of RCT greater than 12 weeks", *Nutr Hosp.* 26(6), pp.1270-1276, 2011. ISSN 0212-1611 • CODEN NUH0EQ S.V.R. 318
13. Bolla, A. M., Caretto, A., Laurenzi, A., Scavini, M., & Piemonti, L. (2019). Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes. *Nutrients*, 11(5), 962. <https://doi.org/10.3390/nu11050962>
14. Sheri R. Colberg, Ronald J. Sigal, Jane E. Yardley, Michael C. Riddell, David W. Dunstan, Paddy C. Dempsey, Edward S. Horton, Kristin Castorino, and Deborah F. Tate, "Physical Activity/Exercise and Diabetes: A Position Statement", *American Diabetes Association Diabetes Care*, 39, pp. 2065–2079, 2016. | DOI: 10.2337/dc16-1728
15. Turner, G., Quigg, S., Davoren, P. et al. Resources to Guide Exercise Specialists Managing Adults with Diabetes. *Sports Med - Open* 5, 20, 2019. <https://doi.org/10.1186/s40798-019-0192-1>
16. Pan, B., Ge, L., Xun, Y. et al., "Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis", *Int J Behav Nutr Phys Act* 15, pp. 72, 2018. <https://doi.org/10.1186/s12966-018-0703-3>
17. NGAYIMBESHA A, BIZIMANA JB, GAKIMA MS, "Effect of Eight Weeks of Exercise Training on Lipid Profile and Insulin Sensitivity in Obese Person", *Int J Sports Exerc Med* 5, pp. 119, 2019. doi. <org/10.23937/2469-5718/1510119>
18. American Friends of Tel Aviv University. (2019, December 3). "Eating in sync with biological clock could replace problematic diabetes treatment: An early-morning, carb-filled meal improves glycemic control among diabetics". *ScienceDaily*, 2019, Retrieved March 22, 2021, from [www.sciencedaily.com/releases/2019/12/191203114510.htm](http://www.sciencedaily.com/releases/2019/12/191203114510.htm)
19. Bolie VW, "Coefficients of normal blood glucose regulation", *J Appl Physiol.*, 16(5), pp. 783–8, 1961.
20. Ackerman E, Gatewood LC, Rosevear JW, Molnar GD, "Model studies of blood-glucose regulation", *Bull Math Biophys.*, 27(1), pp. 21–37, 1965
21. Bergman RN, Ider YZ, Bowden CR, Cobelli C, "Quantitative estimation of insulin sensitivity", *Am J Physiol-Endocrinol Metab*, 236(6), pp. 667, 1979.
22. De Gaetano A, Arino O., "Mathematical modeling of the intravenous glucose tolerance test", *J Math Biol.*, 40(2), pp. 136–68, 2000.
23. Andersen KE, Højbjerg M, "A bayesian approach to Bergman's minimal model", *Insulin*, 50(100), pp. 200, 2002.
24. Bergman RN., "Minimal model: perspective from 2005", *Horm Res Paediatr.*, 64(Suppl. 3), p. 8–15, 2005. doi: 10.115a9/000089312
25. Boutayeb A, Chetouani A., "A critical review of mathematical models and data used in diabetology", *Biomed Eng Online*, 5(1), pp. 43, 2006.
26. Denti P, Bertoldo A, Vicini P, Cobelli C., "Ivgtt glucose minimal model covariate selection by nonlinear mixed-effects approach", *Am J Physiol-Endocrinol Metab*, 298(5), pp. 950–60, 2010.
27. Ajmera I, Swat M, Laibe C, Le Novere N, Chelliah V., "The impact of mathematical modeling on the understanding of diabetes and related complications", *CPT Pharmacometrics Syst Pharmacol*, 2(7), pp.1–14, 2013. doi:10.1038/psp.2013.30
28. Thomaseth K, Brehm A, Pavan A, Pacini G, Roden M, "Modeling glucose and free fatty acid kinetics during insulin-modified intravenous glucose tolerance test in healthy humans: role of counterregulatory response", *Am J Physiol-Regul Integr Comp Physiol*, 307(3), pp. 321–31, 2014.

29. Kelly, R.A., Fitches, M.J., Webb, S.D., et al., "Modelling the effects of glucagon during glucose tolerance testing", *Theor Biol Med Model* 16, pp. 21 2019. <https://doi.org/10.1186/s12976-019-0115-3>
30. Mari, A., Tura, A., Grespan, E., & Bizzotto, R. , "Mathematical Modeling for the Physiological and Clinical Investigation of Glucose Homeostasis and Diabetes", *Frontiers in physiology*, 11, 575789, 2020. <https://doi.org/10.3389/fphys.2020.575789>
31. Ali, A.M., Tahir, F.R., "Computational model of insulin-glucose regulatory system to represent type 1 diabetes mellitus, hypoglycemia and hyperinsulinemia", *Eur. Phys. J. Spec. Top.* 229, pp. 943–952, 2020. <https://doi.org/10.1140/epjst/e2020-900098-6>
32. Xiangyun Shi, Jiaoyan Yao, Xueyong Zhou, "Modeling Impulsive Intake of Glucose: The Significance of Diet to Glucose-Insulin System", *Complexity*, Hindawi Publishing, vol. 2020. ID 6043629, 18 pages, 2020. <https://doi.org/10.1155/2020/6043629>
33. Bergman R. N., "Origins and History of the Minimal Model of Glucose Regulation. *Frontiers in endocrinology*", 11, 583016, 2020. <https://doi.org/10.3389/fendo.2020.583016>
34. American Diabetes Association, "Type 2 Diabetes in Children and Adolescents," *Pediatrics*. March 2000, 105 (3), pp. 671-680, 2020. <https://doi.org/10.1542/peds.105.3.671>

### Appendix 1

VBA code

---

Dim p1, p2, p3, gamma, n, h, i0, g0, gb, ib, al, el As Double

Function f1(t, y1, y2, y3) As Double

f1 = -p1 \* (y1 - gb) - al \* y1 \* y2 - 0.00001 \* el \* (y1 - 94#) \* y3

End Function

Function f2(t, y1, y2, y3) As Double

f2 = -p2 \* y2 + p3 \* (y3 - ib)

End Function

Function f3(t, y1, y2, y3) As Double

If ((y1 - h) > 0) Then

f3 = gamma \* maxm((y1 - h), 0) \* t - n \* (y3 - ib)

Else

f3 = 0

End If

End Function

Function maxm(a, b) As Double

If (a > 0) Then

maxm = a

Else

maxm = b

End If

End Function

Sub rk4()

Dim y1, y2, y3, t As Double

p1 = 0.0296 \* 0.8

p2 = 0.0186 \* 1#

p3 = 0.00000651 \* 1# \* 1#

gamma = 0.00536 \* 1#

h = 90.9

n = 0.23 \* 1#

al = 1#

el = 0#

gb = 94#

ib = 17#

sumg = 0#

sumi = 0

'tine initial



```

t = 0
g0 = 298#
i0 = 333# * 1#
y1 = g0
y2 = 0.0001
y3 = i0
dt = 0.1
For i = 0 To 1200
If (Int(i / 10) * 10 = i) Then
Cells(i / 10 + 2, 1) = t
Cells(i / 10 + 2, 2) = y1
Cells(i / 10 + 2, 3) = y3
Cells(i / 10 + 2, 4) = y2
End If
ga = y1
ia = y3
k1 = dt * f1(t, y1, y2, y3)
l1 = dt * f2(t, y1, y2, y3)
m1 = dt * f3(t, y1, y2, y3)
k2 = dt * f1(t + dt / 2, y1 + k1 / 2, y2 + l1 / 2, y3 + m1 / 2)
l2 = dt * f2(t + dt / 2, y1 + k1 / 2, y2 + l1 / 2, y3 + m1 / 2)
m2 = dt * f3(t + dt / 2, y1 + k1 / 2, y2 + l1 / 2, y3 + m1 / 2)
k3 = dt * f1(t + dt / 2, y1 + k2 / 2, y2 + l2 / 2, y3 + m2 / 2)
l3 = dt * f2(t + dt / 2, y1 + k2 / 2, y2 + l2 / 2, y3 + m2 / 2)
m3 = dt * f3(t + dt / 2, y1 + k2 / 2, y2 + l2 / 2, y3 + m2 / 2)
k4 = dt * f1(t + dt, y1 + k3, y2 + l3, y3 + m3)
l4 = dt * f2(t + dt, y1 + k3, y2 + l3, y3 + m3)
m4 = dt * f3(t + dt, y1 + k3, y2 + l3, y3 + m3)
y1 = y1 + (k1 + 2 * k2 + 2 * k3 + k4) / 6
y2 = y2 + (l1 + 2 * l2 + 2 * l3 + l4) / 6
y3 = y3 + (m1 + 2 * m2 + 2 * m3 + m4) / 6
t = t + dt
sumg = sumg + (ga + y1) / 2 * dt
sumi = sumi + (ia + y3) / 2 * dt

Next i
Cells(1, 5) = sumg
Cells(2, 5) = sumi
Cells(3, 5) = sumg / sumi
End Sub

```